Search Within

Jedd D Wolchok

  1. "American Society of Clinical Oncology"
Formats
  1. Meeting Abstract (134)
  2. Journal Article (36)
  3. Correspondence (1)
Groups
  1. Department of Medicine (171)
  2. GSK Faculty (171)
  3. Melanoma and Immunotherapeutics Service (171)
  4. Solid Tumor Oncology Division (171)
  5. Melanoma Disease Management Team (59)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (52)

More Groups

People
  1. Michael Postow (48)
  2. Paul Chapman (43)
  3. Margaret Callahan (40)
  4. Katherine Panageas (31)
  5. Alexander Shoushtari (21)
  6. Richard Carvajal (18)

More People

Years
  1. 2023 (6)
  2. 2022 (8)
  3. 2021 (4)
  4. 2020 (4)
  5. 2019 (10)
  6. 2018 (15)

More Years

Publications
  1. Journal of Clinical Oncology (171)
Publishers
  1. American Society of Clinical Oncology (171)

Results (171)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
    Meeting Abstract

    Betof Warner, A.; Postow, M. A.; Panageas, K.; Smithy, J. W.; Schoenfeld, A. J.; Wolchok, J. D.; Shoushtari, A. N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Melanomas lacking HLA class I expression and response to checkpoint inhibitor
    Meeting Abstract

    Chapman, P. B.; Jayaprakasam, V. S.; Callahan, M. K.; Shoushtari, A. N.; Postow, M. A.; Lezcano, C.; Wolchok, J. D.; Nandakumar, S.; Chatila, W. K.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib
    Meeting Abstract

    Chapman, P. B.; Klang, M.; Postow, M. A.; Shoushtari, A. N.; Sullivan, R. J.; Wolchok, J. D.; Wong, P.; Callahan, M. K.; Zippin, J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Lao, C. D.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)
    Meeting Abstract

    Smithy, J. W.; Kalvin, H. L.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; Betof Warner, A.; Callahan, M. K.; Momtaz, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
    Journal Article

    Atkins, M. B.; Lee, S.; Chmielowski, B.; Tarhini, A. A.; Cohen, G. I.; Truong, T. G.; Moon, H. H.; Davar, D.; O'Rourke, M.; Stephenson, J. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)
    Meeting Abstract

    Jensen, R. E.; Zheng, Y.; Atkins, M. B.; Chmielowski, B.; Tarhini, A. A.; Truong, T. G.; Davar, D.; O'Rourke, M. A.; Curti, B. D.; Brell, J. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Lewis, K. D.; Grob, J. J.; Rutkowski, P.; Lao, C. D.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192
    Meeting Abstract

    Gibney, G. T.; Lee, S. J.; Atkins, M. B.; Wong, T. Z.; Guerriero, J.; Marron, T. U.; Cohen, G. I.; Truong, T. G.; Carvajal, R. D.; Snyder, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs)
    Meeting Abstract

    Gainor, J. F.; Ravi, A.; Awad, M. M.; Holton, M.; Arniella, M.; Stewart, C.; Freeman, S.; Leshchiner, I.; Chow, A.; Henick, B. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save